Phase I clinical and pharmacokinetic study of the novel raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors

Journal of Clinical Oncology

Volumn 23, Issue 5, 2005, Pages 965-972

  Strumberg, Dirk ^a   Richly, Heike ^a   Hilger, Ralf A ^a   Schleucher, Norbert ^a   Korfee, Sonke ^a   Tewes, Mitra ^a   Faghih, Markus ^a   Brendel, Erich ^a   Voliotis, Dimitris ^a   Haase, Claus G ^a   Schwartz, Brian ^a   Awada, Ahmad ^a   Voigtmann, Rudolf ^a   Scheulen, Max E ^a   Seeber, Siegfried ^a  

^a BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PHORBOL 13 ACETATE 12 MYRISTATE; RAF PROTEIN; SORAFENIB; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ADULT; AGED; ALOPECIA; ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME INHIBITION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLOW CYTOMETRY; HAND FOOT SYNDROME; HUMAN; LIVER CELL CARCINOMA; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PANCREATITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIDE EFFECT; SKIN MANIFESTATION; SKIN TOXICITY; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; ADOLESCENT; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; COLON TUMOR; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; LIVER TUMOR; MIDDLE AGED; PHOSPHORYLATION; RECTUM TUMOR; SAFETY;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; COLONIC NEOPLASMS; DIARRHEA; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FATIGUE; FEMALE; HUMANS; LIVER NEOPLASMS; LYMPHOCYTES; MALE; MIDDLE AGED; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECTAL NEOPLASMS; SAFETY;

EID: 20044382799     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.06.124     Document Type: Article

References (22)

1. Cobb MH: MAP kinase pathways. Prog Biophys Mol Biol 71:479-500, 1999
2. Kolch W: Meaningful relationships: The regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 351:289-305, 2000
3. Hilger RA, Scheuten ME, Strumberg D: The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie 25:511-518, 2002
4. Hindley A, Kolch W: Extracellular signal regulated kinase (ERK)/mitogen activated protein kinase (MAPK)-independent functions of Raf kinases. J Cell Sci 115:1575-1581, 2002
5. Kerkhoff E, Rapp UR: Induction of cell proliferation in quiescent NIH 3T3 cells by oncogenic c-Raf-1. Mol Cell Biol 17:2576-2586, 1997
6. Weinstein-Oppenheimer CR, Blalock WL, Steelman LS, et al: The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors. Pharmacol Ther 88:229-279, 2000
7. Arboleda MJ, Eberwein D, Hibner B, et al: Dominant negative mutants of mitogen-activated protein kinase pathway. Methods Enzymol 332:353-367, 2001
8. Brognard J, Dennis PA: Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small moleculesor dominant negative mutants. Cell Death Differ 9:893-904, 2002
9. Crump M: Inhibition of raf kinase in the treatment of acute myeloid leukemia. Curr Pharm Des 8:2243-2248, 2002
10. Hoshino R, Chatani Y, Yamori T, et al: Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18:813-822, 1999
11. Oka H, Chatani Y, Hoshino R, et al: Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 55:4182-4187, 1995
12. Hood JD, Bednarski M, Frausto R, et al: Tumor regression by targeted gene delivery to the neovasculature. Science 296:2404-2407, 2002
13. Wilhelm S, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum anti-tumor activity and targets raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109, 2004
14. Wilhelm S, Chien DS: BAY 43-9006: Pre-clinical data. Curr Pharm Des 8:2255-2257, 2002
15. Wilhelm S, Housley T: A novel diphenylurea raf kinase inhibitor (RKI) blocks the Raf/MEK/ERK pathway in tumor cells. Proc Am Assoc Cancer Res 41: 2001 (abstr)
16. Gianpaolo-Ostravage C, Carter C, Hibner B: Anti-tumor efficacy of the orally active raf kinase inhibitor BAY 43-9006 in human tumor xenograft models. Proc Am Assoc Cancer Res 42: 2001 (abstr)
17. Trotti A, Byhardt R, Stetz J, et al: Common toxicity criteria, version 2.0: An improved reference grading the acute effects of cancer treatment: Impact on radiotherapy. Int J Radiat Oncol Biol Phys 47:13-47, 2000
18. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
19. Chow S, Patel H, Hedley DW: Measurement of MAP kinase activation by flow cytometry using phosphor-specific antibodies to MEK and ERK: Potential for pharmacodynamic monitoring of signal transduction inhibition. Cytometry 46:72-78, 2001
20. Tannapfel A, Sommerer F, Benicke M, et al: Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 52:706-712, 2003
21. Feng DY, Zheng H, Tan Y, et al: Effect of phosphorylation of MAPK and Stat3 and expression of c-fos and c-jun proteins on hepatocarcinogenesis and their clinical significance. World J Gastroenterol 7:33-36, 2001
22. Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, 2003